Drugs / FLU Q-PAN H5N8 750_B
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05975840 Comparator | Aug 2023 → May 2024 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLU Q-PAN H5N8 750_B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05975840 ↗ |
| Modality | Vaccine | “GSK's AS03-adjuvanted H5N8 vaccine” PMID 42274331 ↗ Jun 2026 |
| Route | Intramuscular | “by intramuscular injection in the non-dominant arm” NCT05975840 ↗ |